MedTrace Logo

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2020-07-09

No results posted yet for this study

Summary

This study will compare hemoglobin a1c (HbA1c) and cardiovascular (CV) outcomes among patients with type 2 diabetes newly initiating a GLP1-receptor agonist or basal insulin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GLP-1 receptor agonist

any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)

DRUG

Insulin

glargine, detemir, neutral protamine Hagedorn (NPH), degludec

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Jessica M Franklin, PHD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04034524 on ClinicalTrials.gov